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Abstract
Introduction Autologous Matrix-Induced Chondrogenesis
(AMIC) is an innovative treatment for localized full-
thickness cartilage defects combining the well-known
microfracturing with collagen I/III scaffold. The purpose of
this analysis was to evaluate the medium-term results of
this enhanced microfracture technique for the treatment of
chondral lesions of the knee.
Methods and materials Patients treated with AMIC
(Chondro-Gide, Geistlich Pharma, Switzerland) were
followed using the AMIC Registry, an internet-based tool
to longitudinally track changes in function and symptoms
by the Lysholm score and VAS.
Results A series of 57 patients was enrolled. The average
age of patients (19 females, 38 males) was 37.3 years (range
17–61 years). The mean defect size of the chondral lesions
was 3.4 cm2 (range 1.0–12.0 cm2). All defects were classi-
fied as grade III (n = 20) or IV (n = 37) according to the
Outerbridge classification. Defects were localized at the
medial (n = 32) or lateral (n = 6) condyle, at the trochlea
(n = 4) and at the patella (n = 15). The follow-up period was
2 years. The majority of patients were satisfied with the
postoperative outcome, reporting a significant decrease of
pain (mean VAS preop = 7.0; 1 year postop = 2.7; 2 years
postop = 2.0). Significant improvement of the mean Lys-
holm score was observed as early as 1 year after AMIC and
further increased values were noted up to 2 years postoper-
atively (preop. 50.1, 1 year postop. 79.9, 2 year postop. 85.2).
Conclusions AMIC is an effective and safe method of
treating symptomatic chondral defects of the knee. How-
ever, further studies with long-term follow-up are needed
to determine if the grafted area will maintain structural and
functional integrity over time.
Level of evidence Prognostic study, Level IV.
Keywords AMIC  Cartilage  Knee  Surgery  Lysholm
score
Introduction
The limited healing potential of articular cartilage is a well-
known problem in orthopedic surgery [26]. Cartilage
degeneration may be accompanied by pain, immobility,
stiffness, loss of quality of life and can potentially lead to
severe osteoarthritis in the long term. A variety of surgical
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techniques that aim for resurfacing and regenerating of
articular cartilage have evolved.
Increasing the intrinsic repair has traditionally been
focused on the recruitment of chondrogenic cells (MSCs)
from the bone marrow by penetration of the subchondral bone
by drilling or microfracturing (MFx) [20]. Currently,
microfracturing is the most commonly used cartilage repair
procedure in cartilage defects [2]. But the deficiencies of
fibrocartilaginous repair tissue inevitably lead to breakdown
under normal joint loading [32]. In microfracturing, chon-
drogenic cells (MSCs) migrate in the fibrin network of the
blood clot [8]. However, the fibrin clot is not mechanically
stable to withstand the tangential forces [11]. An implanted
exogenous scaffold (e.g. a collagen matrix) may improve the
mechanical stability and durability for endogenous cells and
may provide a proper stimulus for chondrogenic differenti-
ation and cartilage regeneration. Autologous Matrix-Induced
Chondrogenesis (AMIC) combines microfracturing with a
collagen I/III matrix (Chondro-Gide, Geistlich Pharma AG,
Wolhusen, Switzerland). The AMIC procedure provides two
major advantages; on one hand, it is a one-step procedure with
no need of cartilage harvesting potentially leading to donor
site morbidity and on the other, it is cost effective with no
need of in vitro cell expansion [4]. In a recent clinical trial we
were able to prove that AMIC is an effective and safe method
for treating symptomatic chondral defects of the knee [16].
The aim of the present study is to update our experience
with the AMIC technique based on the data of the AMIC
registry.
Materials and methods
Study subjects consisted of a cohort of patients treated with
AMIC (Chondro-Gide, Geistlich Pharma, Switzerland)
and enrolled in the AMIC registry since 2005. The registry
is a multicenter program designed to longitudinally track
changes in function and symptoms by the Lysholm score
and VAS. Documentation is done on electronic forms and
surgeons have access via a Web interface. The communi-
cation protocol is SSL encrypted. Surgeons have only
access to their own patients’ data and summary and overall
performance data is anonymized and de-identified. Patient
participation in the registry is voluntary. All participants
were informed and consented for recording and storing of
their data. There is no radiographic follow-up after AMIC
in the registry. Consequently, data regarding the develop-
ment of radiographically verified osteoarthritis are not
available. Radiographic follow-ups were not done because
of financial constraints and also to avoid placing demands
on the surgeons that go beyond their own follow-up rou-
tines. More advanced investigations (e.g. gait analysis and
muscle strength) are also omitted for the same reasons.
Patients were included in the analysis if they had an
AMIC-treated (Outerbridge grade III or IV) lesions in the
knee; data were collected at baseline and at specified fol-
low-up times. The main exclusion criteria from the analysis
were underlying rheumatic disease, total meniscectomy
and revision surgery after the index procedure.
The operative procedure was performed through a mini-
open approach as described previously [16].
Baseline data collection included surgical history, defect
origin, size and location of lesions, concurrent procedures,
age, weight, and sex. Therapeutic success was assessed on
the basis of two different scores: at baseline and follow-up,
patients rated their pain using the Visual Analog Scale
(VAS), with 0 indicating ‘‘no pain’’ and 10 indicating
‘‘pain as bad as it could possibly be’’. The Lysholm score is
a well-validated functional score and was chosen for fol-
low-up [16]. Investigators and research assistants made
extensive efforts to locate subjects, motivate them to stick
to the follow-up protocol and mail follow-up question-
naires to patients. Patients were not financially compen-
sated for their time and effort to complete data collection
forms.
Statistical analysis
The two primary outcomes (pain and Lysholm score) are
described by showing means and SD at each time point of
assessment (baseline, 1 and 2 years post-operative). Fur-
thermore, their mean improvements (along with SD)
between these three time points were also calculated. For
each of the two scores and each time interval (baseline to
1 year, 1–2 years and baseline to 2 years), we used the
two-sided Wilcoxon signed rank tests to test the corre-
sponding null hypotheses of no systematic improvement.
These six tests were performed at the level of 5 %/
6 = 0.833 % each to bound the global type 1 error prob-
ability to 5 % (Bonferroni correction for multiple testing).
Exploratory testing at the 5 % level of hypotheses
related to the two primary outcomes were carried out
without correction for multiple testing: two-sided Mann–
Whitney U test and, where applicable, Kruskal–Wallis test
were used for testing the null hypotheses of no systematic
differences between subgroups (sex, age etc.) in improve-
ment from baseline to 2 years. In addition, Wilcoxon
signed rank tests were performed to test the null hypothesis
of no systematic improvements between baseline and
2 years within subgroup.
Results
Fifty-seven patients with complete data sets at 2-year fol-
low-up could be extracted from the Registry and included
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in the present analysis. Patient data are as follows: 19
females, 38 males; mean BW: female 60 kg (range
40–110) and male 85.5 kg (range 63–118); mean age:
37.3 years (range 17–61 years).
The mean defect size of the chondral lesions was
3.4 cm2 (range 1–9 cm2). All defects were classified as
grade III (n = 20) or IV (n = 37) according to the Out-
erbridge classification [27]. The defects were situated on
the medial femoral condyle (n = 32), on the lateral fem-
oral condyle (n = 6), on the patella (n = 15) and at the
trochlea (n = 4). The chondral lesions were of traumatic
origin in 16 patients (28 %) and idiopathic in 41 patients
(72 %). In 35 patients (61 %) the right knee and in 22
patients (39 %) the left knee was treated. Previous surgical
procedures (n = 35) were diagnostic arthroscopies
(n = 10), partial meniscectomies (n = 5), shaving
(n = 16) and drilling or microfracture (n = 4). When
performing the AMIC procedure, concomitant surgical
procedures such as a patella realignment surgery (n = 2),
corrective osteotomies (n = 3), partial meniscectomies
(n = 6) and anterior cruciate ligament reconstruction
(n = 1) were performed. No complications or adverse
events occurred in the cases studied.
There was significant improvement of knee pain from
the mean baseline value of 7.0 ± 1.8 (range 1 –10) to the
score at the 1-year follow-up (mean 2.7 ± 2.4, range 0–9,
p \ 0.001) and at the 2-year follow-up (mean 2.0 ± 2.1,
range 0–9, p = 0.003). The mean VAS improvement from
baseline to 1 year was 4.2 ± 2.6 (p \ 0.001), from 1 to
2 years 0.5 ± 2.3 (p = 0.003), and from baseline to
2 years 4.7 ± 2.7 (p \ 0.001). Results of the VAS are
summarized in Fig. 1.
The mean preoperative Lysholm score was 50.1 ± 19.6
(range 9–79). A significant improvement was seen in the
follow-up at 1 year with a mean 79.9 ± 21.2 (range
17–100, p \ 0.001) and at 2 years with a mean
85.2 ± 18.4 (range 27–100, p = 0.002). The mean
improvement from baseline to 1 year was 24.2 ± 31.7
(p \ 0.001), from 1 to 2 years 11.0 ± 26.1 (p = 0.002),
and from baseline to 2 years 35.1 ± 19.6 (p \ 0.001).
Figure 1 summarizes the results of the Lysholm score.
In order to determine the influence of age on the post-
operative results, patients were divided into three sub-
groups: patients between 17 and 32 years (group A,
n = 17), patients between 33 and 46 years (group B,
n = 27) and patients between 47 and 65 years (group C,
n = 13). Results are shown in Fig. 2. Mean Lysholm score
improvement from baseline to 2 years was significant in all
groups (group A: 39.3 ± 20.3, p \ 0.001; group B:
36.2 ± 21.2, p \ 0.001; group C: 27.5 ± 11.9,
p = 0.001). No statistically significant between-group
differences from baseline to 2 years were observed
(p = 0.085) with younger patients showing better results.
The mean VAS score also improved significantly in all
groups at 2 years after surgery (group A: 5.1 ± 2.0,
p \ 0.001; group B: 5.0 ± 2.6, p \ 0.001; group C:
3.7 ± 3.2, p = 0.003). Between-group comparison showed
better pain improvement, although not significant, in
younger patients compared to their older counterparts
(p = 0.338).
To elucidate the impact of body weight on the clinical
outcome, patient subgroups were formed as follows for
analysis: males with a body weight of more (n = 18) or
less (n = 12) than 90 kg and females with a body weight
of more (n = 5) or less (n = 14) than 70 kg. Body weight
was not found to significantly influence the improvement
of the Lysholm score (males 34.2 ± 19.0 and 34.2 ± 12.3,
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Fig. 1 Mean and standard deviation values of the clinical outcome
evaluated by the Lysholm and VAS score. Both scores improved
significantly from baseline at 2 years post-operative (Lysholm
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Fig. 2 Effect of age on post-operative clinical outcome evaluated by
Lysholm and VAS score. Patients were divided in three subgroups as
depicted. Mean scores at baseline and at 1 and 2-year follow-up for
the three subgroups are indicated. No statistically significant between-
group differences were observed for Lysholm (p = 0.085) and VAS
(p = 0.338)
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p = 0.517) or the VAS (males 4.5 ± 2.3 and 6.0 ± 2.4,
p = 0.068; females 3.8 ± 2.2 and 4.0 ± 2.4, p = 0.816)
2 years after the index procedure.
In order to investigate the impact of the defect size on
the clinical outcome, patients’ were divided into 3 sub-
groups: group A: defect size [0–3 cm2, group B: defect
size [3–6 cm2, group C: defect size [6–9 cm2. The
between-group results did not differ significantly either in
Lysholm (p = 0.703) or VAS (p = 0.969) scores. The
mean outcome improvement measured by the Lysholm and
VAS score 2 years after the index procedure was
34.8 ± 21.1 and 5.0 ± 1.9 in group A, 33.6 ± 17.1 and
4.4 ± 3.4 in group B and 36.4 ± 19.3 and 4.8 ± 2.3 in
group C.
In order to investigate whether the score results were
dependent on the number of previous operations, the patients
were divided into 2 subgroups (no previous operation
(n = 22) and previous operations (n = 35). There were no
significant differences in Lysholm score improvement from
baseline to 2 years (no previous operation: 29.4 ± 19.4;
previous operation: 38.7 ± 19.1, p = 0.276) and in VAS
pain reduction (no previous operation: 4.6 ± 2.3; previous
operation: 4.9 ± 2.8, p = 0.465). Results are shown in
Fig. 3. Previous surgery affecting the subchondral lamina
(e.g. drilling, microfracture) did not significantly influence
the outcome (n = 10; mean Lysholm score preop:
42.0 ± 22.9; 1-year follow-up: 81.8 ± 22.6; 2-year follow-
up: 86.0 ± 18.6). The mean VAS score improvement in this
group at the 2-year follow-up was 5.8 ± 2.5.
There were no significant differences between male and
female patients in Lysholm score improvement from
baseline to 2 years (female: 36.8 ± 25.9; male:
34.3 ± 15.7, p = 0.416) and in VAS pain reduction
(female: 4.0 ± 2.3; male: 5.1 ± 2.8, p = 0.047). For both
sexes a significant improvement of Lysholm score values
and a significant decline of the VAS values were seen at
follow-up. Figure 4 illustrates the sex-specific differences
of the Lysholm score and the VAS.
Discussion
The AMIC (Autologous Matrix-Induced Chondrogenesis)
technique was first described in 2003 by Behrens et al. and
at present it is widely used on the one hand in its original
form and on the other hand with further developments [2,
5]. Although AMIC is a well-established treatment in
cartilage defect therapy, only sparse published evidence is
found in the literature [16, 24, 31]. In a follow-up trial on
27 patients treated with AMIC in its original form, a sig-
nificant improvement of all clinical scores was seen and
87 % of the patients were highly satisfied with the results
after surgery [16]. MRI analysis showed moderate-to-
complete filling with a normal-to-incidentally hyperintense
signal in most cases [16]. A recent prospective study with
17 patients and a 36-month follow-up reports an
improvement of the Lysholm score from preoperative 38 to
74 at follow-up [31]. 76.5 % of the patients were satisfied
or extremely satisfied with their functional results [31].
To update our experience with the AMIC technique, the
present analysis evaluates mid-term results based on the
AMIC Registry, which is an internet database to longitu-
dinally track changes in function and symptoms by the
Lysholm score and VAS. For selection of patients from
the Registry for analysis in the present study, we used the
criteria of availability of complete patient data and post-
operative results at 2 years. A group of 57 patients met
these criteria and their data were analysed.
The key finding in the present analysis is that an
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VAS Pain (No Previous Surgery, n=22) VAS Pain (Previous Surgery, n=35)
Fig. 3 Mean Lysholm and VAS score in patients without and with
previous surgery. Mean improvement from baseline in both scores
was comparable in the two groups (Lysholm 29.4 ± 19.6 and








































Lysholm (Male, n=38) Lysholm (Female, n=19)
VAS Pain (Male, n=38) VAS Pain (Female, n=19)
Fig. 4 Effect of sex on clinical outcome evaluated by the Lysholm
and VAS score. Mean scores at baseline and at 1 and 2-year follow-up
are shown. Between-group differences of mean improvement from
baseline for Lysholm (female: 36.8 ± 25.9; male: 34.3 ± 15.7,
p = 0.416) and VAS (female: 4.0 ± 2.3; male: 5.1 ± 2.8,
p = 0.047) were not significant
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for the treatment of patients with focal cartilage defects.
Mean Lysholm score values were 85 points at 2-year fol-
low-up compared with mean preoperative values of 50
points. Patients reported significant pain improvement
(VAS) from baseline to 2-year follow-up with a mean 4.7
points. This shows that the loading capacity of the treated
knee joint is well maintained at midterm. The results are in
accordance with our prior published data about AMIC in
cartilage defect therapy of the knee with a follow-up time
up to 60 months; thus, the required 24 months to obtain the
final regenerate quality is fulfilled in this series [6]. The
status of the patients 2 years after cartilage repair is con-
sidered an important indicator for the future outcome [23].
Well-established rating systems have been used in this
analysis to summarize relevant outcome measures. The
combination of the Lysholm score and the VAS have been
recommended in the literature before [14]. The Lysholm
scoring system has demonstrated validity, reliability and
responsiveness to cartilage pathology and treatment [14].
The VAS has widely been used to monitor subjective sat-
isfaction postoperatively [13]. The KOOS score (Knee
Injury and Osteoarthritis Outcome Score) was added to the
AMIC Registry in 2009, so that only short-term follow-up
data are currently available using this scoring system and
thus these data were not analysed the suitability of the
KOOS score for assessing post-operative clinical outcome
in cartilage repair procedures has been demonstrated [3].
Our data demonstrates that, there are patient-specific
and defect-specific factors that influence clinical outcomes
after AMIC. According to available literature, younger
patients with no concomitant ligamentous instability,
meniscal deficiency or patellofemoral malalignment, can
expect the best outcome [19].
Independent of the patients0 age, the Lysholm score
improved in this study, but younger patients showed better
results. This is in accordance with the literature, rating age
as a significant predictor of outcome following cartilage
repair [19]. For example, after matrix-induced autologous
chondrocyte implantation (MACI), significantly better
modified Cincinnati knee scores were seen at the time of
the 1-year follow-up in those who were less than 35 years
old compared to their older counterparts [1].
In our series, no significant impact of the cartilage defect
size on the outcome measures was seen. In a previous
series, patients with a defect size more than 8 cm2 did not
benefit from the enhanced microfracture procedure [16].
Although our data do not support this conclusion, we
believe that the AMIC technique has limited success rates
in extensive cartilage defects, as described e.g. for autol-
ogous chondrocyte implantation (ACI) [22]. A size-based
clinical outcome association was shown when ACI was
compared with microfracture. At 2 years after microfrac-
ture, patients with defects measuring \4 cm2 had
significantly better Lysholm scores and VAS scores than
patients with larger lesions [22].
In a former series, cartilage repair was more efficacious
in males compared to their female counterparts [16]. This
fact is not supported by the current data. Little is known
about sex-specific differences in cartilage repair. Further
studies should elucidate this aspect for a better under-
standing of sex-related dimorphism in knee pathology and
improvement of related surgical treatments. In other fields,
a gender specific research is already on its way [7, 30].
Our results do not support published literature showing
better outcome in patients with fewer previous surgical
procedures prior to cartilage repair. Surgical procedures
prior to cartilage repair were reported to have a significant
impact on postoperative clinical outcome [1], but not in the
context of AMIC [16]. It needs to be emphasized that in
our series previous surgery affecting the subchondral
lamina (e.g. drilling, microfracture) did not negatively
influence the outcome, as reported previously [1]. To our
knowledge, none of the patients had to be revised within
the 2-year follow-up. Besides this, concurrent surgery to
address meniscal lesions did not negatively affect the
clinical outcome of AMIC [19].
Although microfracture demonstrated significantly bet-
ter improvement as compared with e.g. autologous chon-
drocyte implantation at short-term follow-up, the beneficial
results were not maintained at longer follow-up despite
equivalent clinical outcomes, indicating deterioration with
time after microfracture [21]. A recent systematic review
of 28 clinical studies on the clinical outcomes after
microfracture confirmed that microfracture peaks early and
deteriorates with time [25]. Currently no prospective, ran-
domized trial is available to compare microfracture and
AMIC. A potential superiority of the AMIC technique
compared to microfracture especially in the long-term
follow-up would demonstrate the positive effect of the
collagen-I/III-matrix. These advantages are at the moment
only based on experimental data [15, 17].
Current studies suggest modifications to the original
AMIC technique and a switch from conventional micro-
fracturing awls to drilling with K wires [28] [18]. Distinct
differences between microfracture and drilling for acute
subchondral bone structure and osteocyte necrosis were
seen and additional ongoing studies suggest these differ-
ences may significantly affect long-term cartilage repair
outcomes [9]. Most AMIC procedures are performed with a
mini open approach, but an all-arthroscopic AMIC proce-
dure of cartilage defects in the knee has been described
[29]. A modified AMIC technique (called AMIC plus
technique) was described by Dhollander et al. [10]. The
combination of the AMIC technique with platelet-rich
plasma gel resulted in a clinical improvement in all
patients, but was not demonstrated by MRI findings [10].
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In summary, modifications of the original AMIC technique
may improve cartilage repair outcome and optimize the
operative approach, but long-term and randomized studies
are mandatory to confirm the initial results and the reli-
ability of modified AMIC techniques.
There are limitations that need to be acknowledged and
addressed regarding the present analysis. The first limitation
concerns the heterogeneous patient population, which
reflects the situation of patients with an indication for car-
tilage repair surgery. But from another point of view, these
data are representative of the general cartilage patient
population. In contrast, randomized controlled trials do not
necessarily match the majority of patients [12]. The second
limitation has to do with the extent to which the findings can
be generalized beyond the cases studied. The number of
cases is very limited for broad generalization. In general,
the AMIC Registry provides detailed data, but it is also
important to emphasize what the AMIC Registry is not able
to show. There is no radiographic follow-up and conse-
quently the development of osteoarthritis cannot be moni-
tored. An important limitation in registries is a bias due to
gaps in follow-up; our experience has shown that it is dif-
ficult to motivate both patients who are completely satisfied
with restitutio ad integrum of the knee as well as those with
persistent pain and malfunction of the knee to keep the
follow-up appointments. However, these limitations can
also be seen as fruitful avenues for future research.
Conclusion
We present here the mid-term results after AMIC in a
selected set of patients from the AMIC Registry. The key
finding is that AMIC is feasible for the treatment of car-
tilage defects in the knee. The cases analyzed showed a
gradual and significant clinical improvement at follow-ups
1 and 2 years after surgery.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Bartlett W, Skinner JA, Gooding CR, Carrington RW, Flanagan
AM, Briggs TW, Bentley G (2005) Autologous chondrocyte
implantation versus matrix-induced autologous chondrocyte
implantation for osteochondral defects of the knee: a prospective,
randomised study. J Bone Joint Surg Br 87:640–645
2. Behrens P (2005) Matrixgekoppelte Mikrofrakturierung. Arthro-
skopie 18:193–197
3. Bekkers JE, de Windt TS, Raijmakers NJ, Dhert WJ, Saris DB
(2009) Validation of the Knee Injury and Osteoarthritis Outcome
Score (KOOS) for the treatment of focal cartilage lesions.
Osteoarthritis Cartilage 17:1434–1439
4. Benthien JP, Behrens P (2010) Autologous matrix-induced
chondrogenesis (AMIC). A one-step procedure for retropatellar
articular resurfacing. Acta Orthop Belg 76:260–263
5. Benthien JP, Behrens P (2011) The treatment of chondral and
osteochondral defects of the knee with autologous matrix-induced
chondrogenesis (AMIC): method description and recent devel-
opments. Knee Surg Sports Traumatol Arthrosc 19:1316–1319
6. Bentley G, Biant LC, Carrington RW, Akmal M, Goldberg A,
Williams AM, Skinner JA, Pringle J (2003) A prospective, ran-
domised comparison of autologous chondrocyte implantation
versus mosaicplasty for osteochondral defects in the knee. J Bone
Joint Surg Br 85:223–230
7. Boyer KA, Beaupre GS, Andriacchi TP (2008) Gender differ-
ences exist in the hip joint moments of healthy older walkers.
J Biomech 41:3360–3365
8. Cerynik DL, Lewullis GE, Joves BC, Palmer MP, Tom JA (2009)
Outcomes of microfracture in professional basketball players.
Knee Surg Sport Traumatol Arthrosc 17(9):1135–1139
9. Chen H, Sun J, Hoemann CD, Lascau-Coman V, Ouyang W,
McKee MD, Shive MS, Buschmann MD (2009) Drilling and
microfracture lead to different bone structure and necrosis during
bone-marrow stimulation for cartilage repair. J Orthop Res
27:1432–1438
10. Dhollander AA, De Neve F, Almqvist KF, Verdonk R, Lambr-
echt S, Elewaut D, Verbruggen G, Verdonk PC (2011) Autolo-
gous matrix-induced chondrogenesis combined with platelet-rich
plasma gel: technical description and a five pilot patients report.
Knee Surg Sport Traumatol Arthrosc 19:536–542
11. Dorotka R, Windberger U, Macfelda K, Bindreiter U, Toma C,
Nehrer S (2005) Repair of articular cartilage defects treated by
microfracture and a three-dimensional collagen matrix. Bioma-
terials 26:3617–3629
12. EL Engen CN, Aroen A (2010) Knee Cartilage Defect Patients
Enrolled in Randomized Controlled Trials Are Not Representa-
tive of Patients in Orthopedic Practice. Cartilage 1:312–319
13. Flandry F, Hunt JP, Terry GC, Hughston JC (1991) Analysis of
subjective knee complaints using visual analog scales. Am J
Sport Med 19:112–118
14. Fuchs S, Friedrich M (2000) Possible influence of knee scores.
Unfallchirurg 103:44–50
15. Gille J, Meisner U, Ehlers EM, Muller A, Russlies M, Behrens P
(2005) Migration pattern, morphology and viability of cells sus-
pended in or sealed with fibrin glue: a histomorphologic study.
Tissue Cell 37:339–348
16. Gille J, Schuseil E, Wimmer J, Gellissen J, Schulz AP, Behrens P
(2010) Mid-term results of Autologous Matrix-Induced Chon-
drogenesis for treatment of focal cartilage defects in the knee.
Knee Surg Sport Traumatol Arthrosc 18:1456–1464
17. Gille JK, Koeller J, Bos W, Behrens I, Russlies P, Kurz M (2009)
Matrix based cartilage repair techniques—a histological and
biomechanical study in sheep. Cartilage 1:29–42
18. Gomoll AH, Madry H, Knutsen G, van Dijk N, Seil R, Brittberg
M, Kon E (2010) The subchondral bone in articular cartilage
repair: current problems in the surgical management. Knee Surg
Sport Traumatol Arthrosc 18:434–447
19. Harris JD, Siston RA, Pan X, Flanigan DC (2010) Autologous
chondrocyte implantation: a systematic review. J Bone Joint Surg
Am 92:2220–2233
20. Johnson L (1991) Arthroscopic Abrasion Arthroplasty. Raven
Press, New York
21. Knutsen G, Drogset JO, Engebretsen L, Grontvedt T, Isaksen V,
Ludvigsen TC, Roberts S, Solheim E, Strand T, Johansen O
(2007) A randomized trial comparing autologous chondrocyte
92 Arch Orthop Trauma Surg (2013) 133:87–93
123
implantation with microfracture. Findings at five years. J Bone
Joint Surg Am 89:2105–2112
22. Knutsen G, Engebretsen L, Ludvigsen TC, Drogset JO, Grontvedt
T, Solheim E, Strand T, Roberts S, Isaksen V, Johansen O (2004)
Autologous chondrocyte implantation compared with microfrac-
ture in the knee. A randomized trial. J Bone Joint Surg Am
86-A:455–464
23. Kreuz PC, Muller S, Ossendorf C, Kaps C, Erggelet C (2009)
Treatment of focal degenerative cartilage defects with polymer-
based autologous chondrocyte grafts: four-year clinical results.
Arthritis Res Ther 11:R33
24. Kusano T, Jakob RP, Gautier E, Magnussen RA, Hoogewoud H,
Jacobi M (2012) Treatment of isolated chondral and osteochon-
dral defects in the knee by autologous matrix-induced chondro-
genesis (AMIC). Knee Surg Sports Traumatol Arthrosc
20(10):2105–2111
25. Mithoefer K, McAdams T, Williams RJ, Kreuz PC, Mandelbaum
BR (2009) Clinical efficacy of the microfracture technique for
articular cartilage repair in the knee: an evidence-based system-
atic analysis. Am J Sports Med 37:2053–2063
26. Ossendorf C, Kaps C, Kreuz PC, Burmester GR, Sittinger M,
Erggelet C (2007) Treatment of posttraumatic and focal
osteoarthritic cartilage defects of the knee with autologous
polymer-based three-dimensional chondrocyte grafts: 2-year
clinical results. Arthritis Res Ther 9:R41
27. Outerbridge RE (1961) The etiology of chondromalacia patellae.
J Bone Joint Surg Br 43-B:752–757
28. Pascarella A, Ciatti R, Pascarella F, Latte C, Di Salvatore MG,
Liguori L, Iannella G (2010) Treatment of articular cartilage
lesions of the knee joint using a modified AMIC technique. Knee
Surg Sports Traumatol Arthrosc 18:509–513
29. Piontek T, Ciemniewska-Gorzela K, Szulc A, Naczk J, Slo-
mczykowski M (2012) All-arthroscopic AMIC procedure for
repair of cartilage defects of the knee. Knee Surg Sport Traumatol
Arthrosc 20(5):922–925
30. Rosenstein AD, Veazey B, Shephard D, Xu KT (2008) Gender
differences in the distal femur dimensions and variation patterns
in relation to TKA component sizing. Orthopedics 31:652
31. Schiavone Panni A, Cerciello S, Vasso M (2009) The manang-
ement of knee cartilage defects with modified amic technique:
preliminary results. Int J Immunopathol Pharmacol 24:149–152
32. Shapiro F, Koide S, Glimcher M (1993) Cell origin and differ-
entiation in the repair of full-thickness defects of articular carti-
lage. J Bone Joint Surg Am 75(4):532–553
Arch Orthop Trauma Surg (2013) 133:87–93 93
123
